Study ID: COG ACNS1123
Title:

Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)

Description:

The overall goal of the study on the germinoma germ cell tumor is to find out if using chemotherapy with carboplatin and etoposide followed by WVI will work well to get rid of the newly diagnosed localized CNS germinoma for as long as possible, while reducing the frequency and severity of late effects of radiation therapy. The overall goal of the NGGCT study is to is find out how well treatment with WVI works when given to children and young adults with NGGCTs whose disease responds well to standard induction chemotherapy or who have no signs of disease following a second-look surgery. The WVI will use the same total dose as standard treatment, but will give a higher dose of radiation to the site of the disease and a lower dose of radiation to the ventricles. Using WVI instead of CSI or WBI is experimental. Participants in this study have been diagnosed with one of two types of brain cancer, either a germinoma germ cell tumor that is “localized” or a non-germinomatous germ cell tumor (NGGCT) that is “localized”. The term localized means that the tumor has not spread to other parts of the brain or body.

Location:
Sioux Falls Region
Principal Investigator:
Kayelyn Wagner MD
Disease:
CNS (Brain Tumors), GCT (Germ Cell Tumor)
Stage:
Phase II

Status:

Active - Partially Closed to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list